BerGenBio strengthens its leadership team with appointment of Cristina Oliva as Chief Medical Officer PR Newswire BERGEN, Norway, April 11, 2022...
BERGENBIO ASA: BOARD APPROVAL OF 2021 ANNUAL FINANCIAL STATEMENT AND ANNUAL REPORT 2021 PR Newswire BERGEN, Norway, April 7, 2022 BERGEN, Norway...
BERGENBIO ASA: RESULTS FOR THE FOURTH QUARTER AND FULL YEAR 2021 PR Newswire BERGEN, Norway, Feb. 16, 2022 BERGEN, Norway, Feb. 16, 2022...
BerGenBio and Oslo University Hospital Announce the AXL Inhibitor Bemcentinib will be Studied in the EU Funded EU-SolidAct trial in Hospitalised...
BerGenBio Receives FDA Fast Track Designation For Bemcentinib In STK11-mutated Advanced/Metastatic Non-small Lung Cancer (NSCLC) PR...
Bergenbio Presents Pre-clinical and Clinical Data on Bemcentinib in STK11-positive NSCLC at SITC Annual Meeting 2021 PR Newswire BERGEN, Norway...
BerGenBio Presents Encouraging Combined Data for Bemcentinib from Two Phase II COVID-19 Studies at ECCMID PR Newswire BERGEN, Norway, July 12...
Bergenbio Presents Encouraging Updated Preliminary Data From Phase Ii Study In Relapsed Aml Patients At Eha Virtual Meeting PR Newswire BERGEN...
Bergenbio Presents Encouraging Updated Preliminary Data From Phase Ii Study In Relapsed Aml Patients At Eha Virtual Meeting Encouraging updated...
BerGenBio Announces Top Line Data from Phase II Trial Assessing Bemcentinib in Hospitalised COVID-19 Patients PR Newswire BERGEN, Norway, May 18...
BerGenBio Announces Top Line Data from Phase II Trial Assessing Bemcentinib in Hospitalised COVID-19 Patients The trial BGBC020 shows that...
BerGenBio Announces Update From Investigational Phase II Trials Assessing Bemcentinib In Hospitalised COVID-19 Patients PR Newswire BERGEN...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Subscribe to Ad free and enjoy an ad-free experience
Try Now
Keep the Ads